Compositions for the Treatment of Wet Type of Age Related Macular Degeneration (05029)
- *Abstract
-
Features and Benefits
- This invention provides a new method for treatment of AMD, as there is currently no cure for the disease on the market.
- The UofL studies are the first to demonstrate the inhibitory effect of these compositions on angiogenesis.
- The compositions may be administered both systemically or locally.
*This Technology is available for licensing, further development, or industrial partnering*
Technology
This invention provides new methods of treating wet type of age-related macular degeneration by administering adiponectin (APN) or a functional fragment of the APN protein. A pathological complication of AMD is choroidal angiogenesis or neovascularization (CNV). UofL researchers discovered that the level of APN expression is significantly lower in the choroids of a CNV mouse model versus in choroids of control mice and that administration of recombinant adiponectin (rAPN) or APN peptide to CNV mice significantly reduced the size of the CNV. These studies were the first to demonstrate the inhibitory effect of adiponectin on choroidal angiogenesis/neovascularization and thus provide the basis for treating a condition or disease involving angiogenesis, particularly AMD, with the administration of adiponectin.
Markets Addressed
Researchers at the University of Louisville's Ophthalmology and Visual Sciences Department have identified a protein and its functional fragment with inhibitory activity on choroidal angiogenesis, thus providing the basis for a treatment of the wet type of age-related macular degeneration (AMD). Wet type of age-related macular degeneration is an advanced stage of AMD and is responsible for vision loss in 90% of cases of AMD. There are 1.75 million people in the U.S. with AMD with 200,000 new cases every year. By 2020, the number affected with AMD will grow to almost 3 million. This treatment could be widely used for antiangiogenic therapy associated with AMD. The University of Louisville is seeking a business partner interested in developing and commercializing this technology.
Technology Status
- IP Status: Issued U.S. Patent no. 7,964,557; Date of Patent: June 21, 2011
- Development Status: In vivo testing in mice with the full protein and also with peptide fragments
- Fields of Use Available: All
- Country/Region
- USA
